Clinical Trial Detail

NCT ID NCT02115282
Title Exemestane With or Without Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

breast carcinoma

Therapies

Exemestane + Goserelin

Entinostat + Exemestane + Goserelin

Age Groups: adult senior

Additional content available in CKB BOOST